Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Mouth Neoplasms

• Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
• Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
• Addition of Aspirin to Standard of Care in Oral Cancer
• Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
• A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients
• Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
• Preoperative Music Listening in Odontostomatological Surgery (PMLOS)
• Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis
• A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
• Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy
• Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
• Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Stage III-IVB Head and Neck Cancer
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
• Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
• A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
• Topical Aldara (Imiquimod) for Oral Cancer
• Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
• Testing the Addition of an Anti-cancer Drug, BAY1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
• Sodium Thiosulfate for the Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck Undergoing Chemoradiation With Cisplatin
• Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
• Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
• Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
• Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
• Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer
• Using MASL to Combat Oral Cancer
• Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization
• Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
• Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients
• Adjuvant ChemoRadiotherapy Prior to Surgery in Stage IVa Oral Cancers
• Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction
• Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma
• Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
• Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
• Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
• Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
• Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
• Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
• Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
• Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+
• Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
• Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
• Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
• ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
• Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias
• Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
• Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
• Pembrolizumab in Combination With CRT for LA-SCCHN
• Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
• Sentinel Lymph Node Mapping of Oral Cancer Using Near-Infrared Fluorescence Imaging
• Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage
• A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients
• GDF15 Based TPF Induction Chemotherapy for OSCC Patients
• 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
• Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
• GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
• Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High-Risk Appalachian Patients Previously Treated With Surgery For Oral Cancer
• Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
• Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
• Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
• Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
• Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
• Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery
• Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
• Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer
• Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
• Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
• Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment
• TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
• Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
• A Study of High-Risk Oral Cavity Cancer
• A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
• F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
• Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer
• Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
• Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
• Erlotinib Prevention of Oral Cancer (EPOC)
• Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil
• Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
• Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
• Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC
• IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC
• Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC
• Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
• ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer